Modified cytotoxic tall cell line and compositions and methods f

Details Modified cytotoxic tall cell line and compositions and methods f Modified cytotoxic tall cell line and compositions and methods f

1995-01-18

1997-11-04

Schwadron, Ronald B.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

424 931, 424 932, 424 9321, 424 937, 424534, 435 2, 4352401, 4352402, A01N 6300, C12N 508, C12N 500, C12N 522

Patent

active

056836902

ABSTRACT:
The invention provides a modified human cytotoxic T cell line TALL-104, which is characterized by dual activity in vitro and in vivo against tumor cells and virus-infected cells. Also provided are effective and safe methods for use of the modified TALL-104 cells in adoptive therapy of cancer and untreatable viral diseases in MHC-mismatched recipients, and in marrow purging to achieve complete eradication of residual tumor cells from marrows of patients with leukemia and other types of cancer. Also provided are effective and safe methods for use of the modified TALL-104 cells in the manufacture of a veterinary composition for adoptive therapy of canine lymphoma and feline leukemias.

REFERENCES:
patent: 5166059 (1992-11-01), Pastan et al.
patent: 5272082 (1993-12-01), Santoli et al.
Cesano et al., Canc. Res., 56: 3021-3029, 1996.
Foon, Cancer Res., 49:1621-1639, 1989.
Boon, Int. J. Cancer 54:177-180, 1993.
Osband et al., Imm. Today, 11:102-104, 1990.
S. Chan et al, "Mechanism of Interferon-.gamma. Induction by Natural Killer Cell Stimulatory Factor (NKSF): Role of Transcription and mRNA Stability in the Synergistic Interactions Between NKSF and Interleukin-2 or Phorbal Diesters", J. Immunol., 148(1):92-98 (Jan. 1, 1992).
D. Santoli et al, "Synergistic and Antagonistic Effects of IL-1.alpha. and IL-4, Respectively, on the IL-2-Dependent Growth of a T Cell Receptor-.alpha..delta..sup.+ Human T Leukemia Cell Line", J. Immunol., 144(12):4703-4711 (Jun. 15, 1990).
R. O'Connor et al, "Growth Factor-Dependent Differentiation Along the Myeloid and Lymphoid Lineages in an Immature Acute T Lymphocytic Leukemia", J. Immunol., 145(11):3779-3787 (Dec. 1, 1990).
R. O'Connor et al, "Growth Factor Requirements of Childhood Acute T-Lymphoblastic Leukemia: Correlation Between Presence of Chromosomal Abnormalities and Ability to Grow Permanently in Vitro", Blood, 77(7):1534-1545 (Apr. 1, 1991).
A. Cesano et al, "Homing and Progression Patterns of Childhood Acute Lymphoblastic Leukemias in Severe Combined Imunodeficiency Mice", Blood, 77(11):2463-2474 (Jun. 1, 1991).
A. Cesano et al, "Establishment of a Karyotypically Normal Cytotoxic Leukemic T-Cell Line from a T-All Sample Engrafted in SCID Mice", Blood, 81(10):2714-2722 (May 15, 1993).
A. Cesano et al, "Effect of Human Interleukin 3 on the Susceptibility of Fresh Leukemia Cells to Interleukin-2-Induced Lymphokine Activated Killing Activity", Leukemia, 6(6):567-573 (Jun., 1992).
A. Cesano et al, "Cytokine Modulation of the Susceptibility of Acute T-Lymphoblastic Leukemia Cell Lines to LAK Activity", Leukemia, 7(3):404-409 (Mar. 1993).
A. Cesano et al, "Mechanisms of MHC-Non-Restricted Lysis in Two Human
A. Cesano et al, "Two Unique Human Leukemic T-Cell Lines Endowed with a Stable Cytotoxic Function and a Different Spectrum of Target Reactivity Analysis and Modulation of Their Lytic Mechanisms", In Vitro Cell Dev. Biol., 28A:648-656 (Sep.-Oct., 1992).
A. Cesano et al, "Inducible Expression of Granulocyte-Macrophage Colony-Stimulating Factor, Tumor Necrosis Factor-.alpha., and Interferon-.alpha. in Two Human Cytotoxic Leukemic T-Cell Lines", In Vitro Cell Dev. Biol., 28A:657-662 (Sep.-Oct., 1992).
A. Cesano et al, "The Severe Combined Immunodeficient (SCID) Mouse as a Model for Human Myeloid Leukemias", Oncogene, 7:827-836 (May, 1992).
A. Cesano et al, "Treatment of Experimental Blioblastoma with a Human Major Histocompatibility Complex Nonrestricted Cytotoxic T Cell Line", Cancer Research, 55:96-101 (Jan. 1, 1995).
A. Cesano et al, "An Effective and Safe Marrow Purging Strategy Using a Lethally Irradiated Killer T Cell Clone", in Advances in Bone Marrow Purging and Processing, Fourth International Symposium, pp. 165-173 (Oct., 1994).
A. Cesano et al, "Cellular and Molecular Mechanisms of Activation of MHC Nonrestricted Cytotoxic Cells by IL-12", J. Immunology, 151:2943-2957 (Sep., 1993).
P. Greenberg et al, "Effector Mechanisms Operative in Adoptive Therapy of Tumor-Bearing Animals: Implications for the Use of Interleukin-2", J. Biol. Resp. Modifiers, 3(5):455-461 (1984).
J. Klarnet et al, "Helper-Independent CD8+ Cytotoxic T Lymphocytes Express IL-1 Receptors and Require IL-1 for Secretion of IL-2", J. Immunol., 142(7):2187-2191 (Apr. 1, 1989).
M. Cheever et al, "Potential Uses of Interleukin 2 in Cancer Therapy", Immunobiol., 172:365-382 (1986).
"First AIDS Gene-Transfer Clinical Comes Before RAC", Biothechnology Newswatch, 11(22):1-3 (Nov. 18, 1991).
"RAC Phases Out Human Gene Therapy Unit; Approves Six New Protocols", Biotechnology Newswatch, 12(4):9-10 (Feb. 17, 1992).
D. Ojcius et al, "Cell-Mediated Killing: Effector Mechanisms and Mediators", Cancer Cells, 2(5):138-145 (May, 1990).
E. Grimm et al, "Lymphokine-Activated Killer Cell Phenomenon: Lysis of Natural Killer-Resistant Fresh Solid Tumor Cells by Interleukin 2-Activated Autologous Human Peripheral Blood Lymphocytes", J. Exp. Med., 155:1823-1841 (Jun., 1982).
S. Rosenberg, "Lymphokine-Activated Killer Cells: A New Approach to Immunotherapy of Cancer", J. Natl. Can. Inst., 74(4):595-603 (Oct., 1985).
S. Rosenberg et al, "Special Report--Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer", New Engl. J. Med., 313(23):1485-1492 (Dec. 5, 1985).
S. Rosenberg et al, "A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone", New Engl. J. Med., 316(15):889-897 (Apr. 9, 1987).
S. Rosenberg, "What's New in General Surgery: The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2", Ann. Surg., 208(2):121-135 (Aug., 1988).
S. Rosenberg et al, "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients", Ann. Surg., 210(4):474-485 (Oct., 1989).
M. Rosenstein et al, "Lymphokine-Activated Killer Cells: Lysis of Fresh Syngeneic Natural Killer-Resistant Murine Tumor Cells by Lymphocytes Cultured in Interleukin 2", Cancer Res., 44:1946-1953 (May, 1984).
J. Mule et al, "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2", Science, 225:1487-1489 (Sep. 28, 1984).
R. Lafreniere et al, "Successful Immunotherapy of Murine Experimental Hepatic Metastases with Lymphokine-Activated Killer Cells and Recombinant Interleukin 2", Cancer Res., 45:3735-3741 (Aug. 1985).
A. Mazumder et al, "Successful Immunotherapy of Natural Killer-Resistant Established Pulmonary Melanoma Metastases by the Intravenous Adoptive Transfer of Syngeneic Lymphocytes Activated in vitro by Interleukin 2", J. Exp. Med., 159:495-507 (Feb., 1984).
W. West et al, "Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer", New Engl. J. Med., 316(15):898-905 (Apr. 9, 1987).
S. Topalian et al, "Expansion of Human Tumor Infiltrating Lymphocytes for Use in Immunotherapy Trials", J. Immunol. Meth. 102:127-141 (1987).
J. Mule et al, "Immunotherapy with Lymphokine Combinations", Important Adv.
K. Itoh et al, "Interleukin 2 Activation of Cytotoxic T-Lymphocytes Infiltrating into Human Metastatic Melanomas", Cancer Res., 46:3011-3017 (Jun., 1986).
R. Lee et al, "Cardiorespiratory Effects of Immunotherapy with Interleukin-2", J. Clin. Oncol., 7(1):7-20 (Jan., 1989).
M. Lotze et al, "Mechanisms of Immunologic Antitumor Therapy: Lessons from the Laboratory and Clinical Applications", Hum. Immunol., 28:198-207 (1990).
J. Gootenberg et al, "A Biochemical Variant of Human T Cell Growth Factor Produced by a Cutaneous T Cell Lymphoma Cell Line", J. Immunol., 129(4):1499-1505 (Oct., 1982).
S. Arya et al, "T-Cell Growth Factor Gene: Lack of Expression in Human T-Cell Leukemia-Lymphoma Virus-Infected Cells", Science, 223:1086-1087 (Mar., 1984).
Y. Kaufmann et al, "Interleukin 2 Induces Human Acute Lymphocytic Leukemia Cells to Manifest Lymphokine-Activated-Killer (LAK) Cytotoxicity", J. Immunol., 139(3):977-982 (Aug. 1, 1987).
A. Kasid et al, "Human Gene Transfer: Characterization of Human Tumor-Infiltrating Lym

Affiliated with

Also associated with

Rating

Modified cytotoxic tall cell line and compositions and methods f does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified cytotoxic tall cell line and compositions and methods f, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified cytotoxic tall cell line and compositions and methods f will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1830924